OMGA 241220 5.00P (OMGA241220P5000) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

OMGA241220P5000

Watchlist

0.00
0.000.00%

15min DelayClose Dec 11 09:30 ET

0.00High0.00Low

Intraday

5D
Daily

No Data

News

Omega Therapeutics Appoints New Director Ravi Mehrotra
TipRanksDec 6 17:29 ET
Flagship Pioneering Announces Two New Agreements With Ampersand Biomedicines and Montai Therapeutics Under Its Strategic Partnership With Pfizer
PR NewswireNov 20 06:30 ET
Raymond James Downgrades Omega Therapeutics(OMGA.US) to Hold Rating
Moomoo NewsNov 15 09:31 ET · Ratings
Raymond James Downgrades Omega Therapeutics to Market Perform From Outperform
MT NewswiresNov 15 09:01 ET
Piper Sandler Maintains Omega Therapeutics(OMGA.US) With Buy Rating, Cuts Target Price to $4
Moomoo NewsNov 15 07:33 ET · Ratings
Piper Sandler Remains a Buy on Omega Therapeutics (OMGA)
TipRanksNov 15 07:06 ET · Ratings

Comments

104294857

Nov 26 06:40

$Omega Therapeutics (OMGA.US)$ about to fly 🚀 take note guyss

Jaguar8

Nov 20 05:46

NEWS

$Omega Therapeutics (OMGA.US)$
Flagship Pioneering Announces Two New Agreements with Ampersand Biomedicines and Montai Therapeutics Under its Strategic Partnership with Pfizer
Ampersand's AND™ Platform will be used to identify programmed biologics for the
treatment of obesity-related targets
Montai's CONECTA™ AI platform will be used to identify small molecules directed to a
potential Non-Small Cell Lung Cancer-related target
Collaborations will leverage Pfizer's deep expertise in early di...

Jaguar8

Nov 14 15:06

NEWS

$Omega Therapeutics (OMGA.US)$
Omega Therapeutics Announces Successful Completion of Phase 1 Trial for Novel Epigenomic Controller, Prioritized Pipeline, Leadership Changes, and Third Quarter 2024 Financial Results
Positive
Phase 1 MYCHELANGELO trial showed 50% disease control rate in HCC patients
Reduced net loss to $16.4M in Q3 2024 from $22.2M in Q3 2023
R&D expenses decreased by $3.7M compared to Q3 2023
G&A expenses reduced by $1.0M compared to Q3 2023
Ongoing collaboration with Novo Nor...

Jaguar8

Oct 22 12:14

Hey 👋

$Omega Therapeutics (OMGA.US)$

Clintzilla

Oct 19 12:22

$Omega Therapeutics (OMGA.US)$ interesting